| abstract |
The present invention provides a compound having the general structure A or a pharmaceutically acceptable salt thereof: Het-LP (A) wherein Het is an aromatic moiety comprising a heterocyclic structure that mimics ATP; P is a docking site-derived peptide or docking site peptidomimetic, and L is a linking moiety that links the ATP mimetic to the docking site peptide moiety. Compounds having the general structure A can serve as inhibitors of kinases such as the kinases JNK, Erk and P38. |